Description
Anti-Endothelial Monocyte Activating Polypeptide II Antibody, Non-Fucosylated (BioBet-809ZP) is a humanized monoclonal IgG antibody against Endothelial monocyte activating polypeptide II. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Autoimmune Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Endothelial monocyte activating polypeptide II antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EMAP II
Full Name
Endothelial monocyte activating polypeptide II
Background
Endothelial monocyte-activating polypeptide (EMAP) II has recently been identified as an antiangiogenic factor in tumor vascular development. EMAP II is a putative negative modulator of lung vascular growth.
Alternative Names
EMAP II; Endothelial monocyte activating polypeptide II
Gene ID
1956
Cellular Localization
Nucleus, Golgi apparatus, Cytosol, Extracellular region or secreted, Endoplasmic reticulum
Involvement in Disease
Diseases associated with SEC23B include Anemia, Congenital Dyserythropoietic, Type Ii and Cowden Syndrome 7.
Related Pathways
Its related pathways are Sterol Regulatory Element-Binding Proteins (SREBP) signalling and Delta508-CFTR traffic / ER-to-Golgi in CF.
Function
A component of coat protein complex II (COPII), it promotes the formation of transport vesicles from the endoplasmic reticulum (ER). The shell has two main functions, physically deforming the endoplasmic reticulum membrane into vesicles and selecting cargo molecules for transport to the Golgi complex.
Post-translational modifications
Cleaved by caspase-7 in response to apoptosis to produce EMAP-II.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-809ZP
Description
This is a humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II.
Antibody Indication
Autoimmune Diseases
